ZM241385 25 mg | 95.28%
TargetMol
ZM-241385 is a high-affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM241385
Search Results
ZM241385 100 mg | 95.28%
TargetMol
ZM-241385 is a high-affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM241385
Mebhydrolin 100 mg | 99.73%
TargetMol
Mebhydrolin
Mebhydrolin 200 mg | 99.73%
TargetMol
Mebhydrolin
Mebhydrolin 500 mg | 99.73%
TargetMol
Mebhydrolin
Ibrutinib 100 mg | 99.79%
TargetMol
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
More Information Supplier PageIbrutinib
Ibrutinib 200 mg | 99.79%
TargetMol
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
More Information Supplier PageIbrutinib
Ibrutinib 50 mg | 99.79%
TargetMol
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
More Information Supplier PageIbrutinib
Trametinib 100 mg | 99.88%
TargetMol
Trametinib is an ATP-noncompetitive inhibitor of MEK 1/2 (IC50s: 0.7/0.9 nM). It shows low inhibition for more than 180 kinases, including B-Raf, c-Raf, and MEK5.
More Information Supplier PageTrametinib
Trametinib 10 mg | 99.88%
TargetMol
Trametinib is an ATP-noncompetitive inhibitor of MEK 1/2 (IC50s: 0.7/0.9 nM). It shows low inhibition for more than 180 kinases, including B-Raf, c-Raf, and MEK5.
More Information Supplier PageTrametinib